TURN THERAPEUTICS INC
TTRXNASDAQTrading Snapshot
- Day Range
- $12.84 – $13.11
- 52-Week Range
- $2.57 – $26.50
- Volume
- $5.02B
- Avg Volume
- $4.09B
- Shares Outstanding
- 29.8M
- Next Earnings
- Dec 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $29M
- Last Q Revenue
- $7M
- P/E Ratio
- -44.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.28
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +120.8%
Why Investors Own TTRX
- ✓High-growth profile — revenue up -9.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 70% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TURN THERAPEUTICS INC
TTRX
StockOtter · stockotter.spaceAbout TURN THERAPEUTICS INC
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin d
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D.
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today an
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, toda
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today pr
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
Turn Therapeutics NASDAQ: TTRX outlined the final stage two design and data-driven expansion of its GX-03 phase II program in atopic dermatitis during an investor update call, saying the revised approach was informed by